Drug Trial Radar · NCT05118776
Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM
Last checked: Nov 19, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
136
Actual
Start
Jan 21, 2022
Primary completion
Jun 2025
Study completion Jun 2025
Sponsor
- Lead sponsor
- Ascletis Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, controlled and multi-center Phase III clinical trial to evaluate the safety and efficacy of ASC40 tablets combined with bevacizumab in the treatment of adult patients with recurrent glioblastoma. After standard radiotherapy and chemotherapy (temozolomide), the subject first experienced clinical recurrence or progression.
Conditions
- Recurrent Glioblastoma
Interventions
ASC40 tabletsDrug
ASC40 tablets administered orally once daily
Placebo tabletsDrug
Placebo administered orally once daily.
BevacizumabDrug
Bevacizumab once every 2 weeks, intravenous drip.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survivalTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months
- Total survivalTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 10 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tiantan Hospital,Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.